Accuray (ARAY)
(Delayed Data from NSDQ)
$1.94 USD
-0.09 (-4.43%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.94 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARAY 1.94 -0.09(-4.43%)
Will ARAY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARAY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARAY
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
ARAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?
Accuray (ARAY) Up 2% Since Last Earnings Report: Can It Continue?
New Strong Sell Stocks for May 31st
Other News for ARAY
Heartland Value Fund Q2 2024 Portfolio Manager Commentary
Heidelberg University Hospital in Germany Invests in Fourth Accuray Radiotherapy Device, the Radixact® System, to Improve Cancer Patient Care
Accuray and TrueNorth Medical Physics Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients
Accuray partners with TrueNorth Medical to provide radiation oncology support
Accuray and TrueNorth Medical Physics partner in radiation oncology support